Despite the approval of KRASG12C inhibitors, adagrasib (MRTX849) and sotorasib (AMG510) for NSCLC patients harboring KRASG12C mutations, KRAS alterations are still related to unfavorable therapeutic outcomes and improvement in survival rates in this LUAD subtype remains an unmet clinical need [4, 5]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.